Ypb's closest competitor DTZ has a mc 10x ypb. Yet DTZ's quarterly rev is only slightly higher. $320k V $260k ($AUD).
Both firms do regular CR as they both need extra cash to fund growth. On this basis, it appears Ypb is massively undervalued. DYOR.
- Forums
- ASX - By Stock
- CDE
- Ann: Quarterly Activities Report & Appendix 4C
Ann: Quarterly Activities Report & Appendix 4C, page-15
Featured News
Add CDE (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.641M |
Open | High | Low | Value | Volume |
0.1¢ | 0.1¢ | 0.1¢ | $750 | 749.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
18 | 25358008 | 0.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.2¢ | 35596219 | 29 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
18 | 25358008 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.002 | 35596219 | 29 |
0.003 | 6751776 | 9 |
0.004 | 9304781 | 7 |
0.005 | 2715000 | 6 |
0.006 | 55000 | 1 |
Last trade - 10.02am 13/11/2024 (20 minute delay) ? |
Featured News
CDE (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online